ArticleInternational journal of clinical pharmacy2018
Increased prescribing of ursodeoxycholic acid in Norway.
Article in International journal of clinical pharmacy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Ursodeoxycholic acid is a hydrophilic bile acid prescribed for a variety of cholestatic liver disorders, although with variable clinical evidence with regards to efficacy. Objective The aim of this study was to investigate the prescription pattern of ursodeoxycholic acid in Norway over the last 13 years. Method Information on the prescribing of ursodeoxycholic acid was extracted from the Norwegian Prescription Database. Data was obtained on the number of individuals who had at least one prescription of ursodeoxycholic acid for any indication dispensed per year in the period 2004-2017. Results The period 2004-2017 witnessed an overall rise in the prevalence of ursodeoxycholic acid prescribing of 237%. With regards to development in prescribing across different age cohorts there is an increase in prescribing in all age groups, although the trend seems to be levelling off in some cohorts. Conclusion Considering the variable clinical evidence of the efficacy of ursodeoxycholic acid, the increase in prescribing is interesting and should prompt vigilance and further research with regards to its long term effects on clinical outcomes.
Indexed as
Identifiers
30267256What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.